NCT04161755View on ClinicalTrials.gov

Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

December 13, 2019

Primary Completion Date

November 11, 2025

Study Completion Date

November 11, 2025

Conditions
Pancreatic Cancer
Interventions
DRUG

Atezolizumab

Atezolizumab will be administered 6 weeks post-tumor resection (+/- 2 weeks)

BIOLOGICAL

RO7198457

RO7198457 will be administered 9 weeks post-tumor resection (+/- 2 weeks)

DRUG

mFOLFIRINOX

mFOLFIRINOX regimen will be administered 21 weeks post-tumor resection (+/- 2 weeks)

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11570

Memorial Sloan Kettering Nassau (All Protocol Activities), Rockville Centre

11725

Memorial Sloan Kettering Cancer Center @ Commack (All Protocol Activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Massachusetts Institute of Technology

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER